Exposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaques

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Hsu, Mayla ^a   Keele, Brandon F ^b   Aravantinou, Meropi ^a   Krawczyk, Noa ^a   Seidor, Samantha ^a   Abraham, Ciby J ^a   Zhang, Shimin ^a   Rodriguez, Aixa ^a   Kizima, Larisa ^a   Derby, Nina ^a   Jean Pierre, Ninochka ^a   Mizenina, Olga ^a   Gettie, Agegnehu ^c   Grasperge, Brooke ^d   Blanchard, James ^d   Piatak Jr , Michael J ^b   Lifson, Jeffrey D ^b   Fernández Romero, José A ^a   Zydowsky, Thomas M ^a   Robbiani, Melissa ^a  

^a POPULATION COUNCIL   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; MIV 150; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GENE MUTATION; GROWTH INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; NONHUMAN; NUCLEOTIDE SEQUENCE; RHESUS MONKEY; RNA SEQUENCE; SEQUENCE ANALYSIS; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS TRANSMISSION;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; DRUG RESISTANCE, VIRAL; FEMALE; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; MUTATION; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TIME FACTORS; UREA; VIRAL LOAD;

EID: 84897824849     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089300     Document Type: Article

References (50)

1. Celum C, Baeten JM (2012) Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis 25: 51-57.
2. Supervie V, Barrett M, Kahn JS, Musuka G, Moeti TL, et al. (2011) Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance. Sci Rep 1: 185.
3. Manasa J, Lessells RJ, Skingsley A, Naidu KK, Newell ML, et al. (2013) High-Levels of Acquired Drug Resistance in Adult Patients Failing First-Line Antiretroviral Therapy in a Rural HIV Treatment Programme in KwaZulu-Natal, South Africa. PLoS One 8: e72152.
4. Coetzer M, Westley B, Delong A, Tray C, Sophearin D, et al. (2013) Extensive Drug Resistance in HIV-Infected Cambodian Children Who Are Undetected as Failing First-Line Antiretroviral Therapy by WHO 2010 Guidelines. AIDS Res Hum Retroviruses.
5. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, et al. (2012) Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 380: 1250-1258.
6. Alencar C, Sabino E, Carvalho S, Leao S, Carneiro-Proietti A, et al. (2013) HIV genotypes and primary drug resistance among HIV seropositive blood donors in Brazil: role of infected blood donors as sentinel populations for molecular surveillance of HIV. J Acquir Immune Defic Syndr.
7. Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, et al. (2011) Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses 27: 5-12.
8. Hamers RL, Kityo C, Lange JM, de Wit TF, Mugyenyi P (2012) Global threat from drug resistant HIV in sub-Saharan Africa. BMJ 344: e4159.
9. Saenz RA, Bonhoeffer S (2013) Nested model reveals potential amplification of an HIV epidemic due to drug resistance. Epidemics 5: 34-43.
10. Cherutich P, Kaiser R, Galbraith J, Williamson J, Shiraishi RW, et al. (2012) Lack of knowledge of HIV status a major barrier to HIV prevention, care and treatment efforts in Kenya: results from a nationally representative study. PLoS One 7: e36797.
11. Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW (2013) Antiretroviral Therapy and Pre-exposure Prophylaxis: Combined Impact on HIV-1 Transmission and Drug Resistance in South Africa. J Infect Dis.
12. Singer R, Derby N, Rodriguez A, Kizima L, Kenney J, et al. (2011) The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J Virol 85: 5504-5512.
13. Singer R, Mawson P, Derby N, Rodriguez A, Kizima L, et al. (2012) An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci Transl Med 4: 150ra123.
14. Kenney J, Singer R, Derby N, Aravantinou M, Abraham CJ, et al. (2012) A Single Dose of a MIV-150/Zinc Acetate Gel Provides 24 h of Protection Against Vaginal Simian Human Immunodeficiency Virus Reverse Transcriptase Infection, with More Limited Protection Rectally 8-24 h After Gel Use. AIDS Res Hum Retroviruses 28: 1476-1484.
15. Kenney J, Aravantinou M, Singer R, Hsu M, Rodriguez A, et al. (2011) An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One 6: e15835.
16. Crostarosa F, Aravantinou M, Akpogheneta OJ, Jasny E, Shaw A, et al. (2009) A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy. PLoS One 4: e8060.
17. Hsu M, Aravantinou M, Menon R, Seidor S, Goldman D, et al. (2013) A combination microbicide gel protects macaques against vaginal SHIV-RT infection, but only partially reduces HSV-2 infection after a single high-dose co-challenge. AIDS Res Hum Retroviruses.
18. Hardy E, Hebling EM, Sousa MH, Almeida AF, Amaral E (2007) Delivery of microbicides to the vagina: difficulties reported with the use of three devices, adherence to use and preferences. Contraception 76: 126-131. (Pubitemid 47082515)
19. Derby N, Zydowsky T, Robbiani R (2013) In search of the optimal delivery method for anti-HIV microbicides: are intravaginal rings the way forward? Expert Review of Anti-Infective Therapy 11: 5-8.
20. Uberla K, Stahl-Hennig C, Bottiger D, Matz-Rensing K, Kaup FJ, et al. (1995) Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci U S A 92: 8210-8214.
21. Turville SG, Aravantinou M, Miller T, Kenney J, Teitelbaum A, et al. (2008) Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One 3: e3162.
22. Animal Welfare Act and Regulation of 2001. In: Code of Federal Regulations t, chapter 1, subchapter A: animals and animal products, editor. Beltsville, MD: U.S. Department of Agriculture.
23. (2011) Guide for the Care and Use of Laboratory Animals: Eighth Edition: The National Academies Press.
24. Aravantinou M, Singer R, Derby N, Calenda G, Mawson P, et al. (2012) The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection. AIDS Res Hum Retroviruses 28: 1467-1475.
25. Frank I, Piatak M Jr, Stoessel H, Romani N, Bonnyay D, et al. (2002) Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): differential intracellular fate of virions in mature and immature DCs. J Virol 76: 2936-2951. (Pubitemid 34184879)
26. Kumar N, Didolkar AK, Ladd A, Thau R, Monder C, et al. (1990) Radioimmunoassay of 7 alpha-methyl-19-nortestosterone and investigation of its pharmacokinetics in animals. J Steroid Biochem Mol Biol 37: 587-591.
27. Dupnik KM, Gonzalez MJ, Shafer RW (2001) Most multidrug-resistant HIV-1 reverse transcriptase clones in plasma encode functional reverse transcriptase enxzymes. Antivrial Therapy 6: 42.
28. Trkola A, Matthews J, Gordon C, Ketas T, Moore JP (1999) A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol 73: 8966-8974. (Pubitemid 29487049)
29. Fernandez-Romero JA, Thorn M, Turville SG, Titchen K, Sudol K, et al. (2007) Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis 34: 9-14. (Pubitemid 46041501)
30. Shafer RW (2006) Rationale and Uses of a Public HIV Drug-Resistance Database. J Infect Dis 194: S51-58.
31. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552-7557. (Pubitemid 351830056)
32. Cline AN, Bess JW, Piatak M Jr, Lifson JD (2005) Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol 34: 303-312. (Pubitemid 41179592)
33. Dobard C, Sharma S, Martin A, Pau CP, Holder A, et al. (2012) Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol 86: 718-725.
34. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
35. Weiss J, Haefeli WE (2013) Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents 41: 484-487.
36. Xu HT, Oliveira M, Asahchop EL, McCallum M, Quashie PK, et al. (2012) Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase. J Virol 86: 12983-12990.
37. Rath BA, Yousef KP, Katzenstein DK, Shafer RW, Schutte C, et al. (2013) In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis. PLoS One 8: e61102.
38. Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ (2000) Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol 74: 6262-6268. (Pubitemid 30429790)
39. Ambrose Z, Palmer S, Boltz VF, Kearney M, Larsen K, et al. (2007) Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol 81: 12145-12155. (Pubitemid 350085830)
40. Kearney M, Spindler J, Shao W, Maldarelli F, Palmer S, et al. (2011) Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy. J Virol 85: 1067-1076.
41. Xu HT, Colby-Germinario SP, Asahchop EL, Oliveira M, McCallum M, et al. (2013) The Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase and their Interactions with the M184I Mutation in Defining Patterns of Resistance to the Non-Nucleoside Reverse Transcriptase Inhibitors Rilpivirine and Etravirine. Antimicrob Agents Chemother.
42. Kulkarni R, Babaoglu K, Lansdon EB, Rimsky L, Van Eygen V, et al. (2012) The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. J Acquir Immune Defic Syndr 59: 47-54.
43. McCallum M, Oliveira M, Ibanescu RI, Kramer VG, Moisi D, et al. (2013) Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase. Antimicrob Agents Chemother 57: 4681-4688.
44. de Bethune MP (2010) Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res 85: 75-90.
45. Boltz VF, Ambrose Z, Kearney MF, Shao W, Kewalramani VN, et al. (2012) Ultrasensitive allele-specific PCR reveals rare preexisting drug-resistant variants and a large replicating virus population in macaques infected with a simian immunodeficiency virus containing human immunodeficiency virus reverse transcriptase. J Virol 86: 12525-12530.
46. Gianella S, Delport W, Pacold ME, Young JA, Choi JY, et al. (2011) Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol 85: 8359-8367.
47. Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, et al. (2013) Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10: 22.
48. Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, et al. (2013) Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness. Antimicrob Agents Chemother 57: 2654-2663.
49. Tsibris AM, Hu Z, Paredes R, Leopold KE, Putcharoen O, et al. (2012) Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures. J Virol 86: 6416-6426.
50. Arts EJ (2012) Commentary on the role of treatment-related HIV compensatory mutations on increasing virulence: new discoveries twenty years since the clinical testing of protease inhibitors to block HIV-1 replication. BMC Med 10: 114.